Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glyxambi

FDA says final mobile app guidance just weeks away

And tells Congress only a fraction of mobile apps will need regulating

- PMLiVE

Additional 2,300 jobs to go at AstraZeneca

Soriot sets out strategy to return to growth

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

Improved health communications needed with the UK’s South Asian communities

Red Door Communications launches ethnic minority outreach programme

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

FDA explains draft Alzheimer’s guidance in NEJM editorial

Intends to relax requirements in patient function and cognition

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

Astellas files diabetes drug ipragliflozin in Japan

Its SGLT2 inhibitor could beat AZ-BMS' rival Forxiga to debut in that market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links